Challenges remain in current cervical cancer screening approaches that can now be addressed with more advanced technologies.
The molecular and biomarker-based tests in the Roche Cervical Cancer Portfolio bring greater diagnostic certainty to cervical cancer screening to guide clinicians and women along each step, removing ambiguity that can arise in current testing approaches.